Palvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny.
Latest Palvella Therapeutics news
We have not published a story on Palvella Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $187.8 million, plus short-term investments of $62.8 million, $250.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Palvella Therapeutics
Is Palvella Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Nov 7, 2024: "Pieris (now Palvella Therapeutics) files merger partner's Phase 3 dosing news". The story links the filing or release it is based on. Read the story.
Is Palvella Therapeutics involved in a lawsuit?
Our latest story on this, dated Nov 7, 2024: "Pieris (now Palvella Therapeutics) files merger partner's Phase 3 dosing news". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Palvella Therapeutics?
Palvella Therapeutics, Inc. trades under the ticker PVLA on NASDAQ.
Where is Palvella Therapeutics listed?
Palvella Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PI6; LSX:A40RA6.
What is the SEC CIK of Palvella Therapeutics?
The SEC Central Index Key (CIK) for Palvella Therapeutics, Inc. is 1583648. Its filings are on SEC EDGAR.
How many shares does Palvella Therapeutics have outstanding?
14,408,407 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Palvella Therapeutics listed under?
Our directory records Palvella Therapeutics, Inc. under United States.
What does Palvella Therapeutics do?
Our directory classifies Palvella Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Palvella Therapeutics?
The ISIN recorded for Palvella Therapeutics, Inc. is US6979471090.
Does aibio.space cover Palvella Therapeutics?
aibio.space lists Palvella Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Palvella Therapeutics incorporated?
SEC records list its state or country of incorporation as NV.
Is Palvella Therapeutics profitable?
Palvella Therapeutics, Inc. reported a net loss of $41.7 million for the fiscal year ended Dec 31, 2025, and used $25.0 million of cash in operations, per its annual report to the SEC.
How much does Palvella Therapeutics spend on research and development?
$22.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Palvella Therapeutics have?
$250.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Palvella Therapeutics (PVLA) stock news?
Our latest story on Palvella Therapeutics, dated Nov 7, 2024: "Pieris (now Palvella Therapeutics) files merger partner's Phase 3 dosing news". Palvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny. Source.
Investor discussion: Palvella Therapeutics
Members talk about Palvella Therapeutics (PVLA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Palvella Therapeutics, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.02,5.03,5.07,8.01,9.01). Source
Mergers
Reported a merger or acquisition agreement. SEC Form 425. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PVLA on TradingView.
SEC filings and registration
SEC name
Palvella Therapeutics, Inc.
CIK
1583648
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PVLA (Nasdaq)
State or country of incorporation
NV
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
353 W. LANCASTER AVENUE, WAYNE, PA, 19087
Phone
(484) 253-1461
Shares outstanding
14,408,407 as of 2026-07-31 (10-Q filed 2026-08-04)
Former names
PIERIS PHARMACEUTICALS, INC.; Marika Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Palvella Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PVLA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio